FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379522772> ?p ?o ?g. }

• W4379522772 endingPage "379" @default.
• W4379522772 startingPage "379.1" @default.
• W4379522772 abstract "Background Chronic parenchymal lung disease (LD) is a new emerging severe life-threatening complication of sJIA. The number of sJIA patients with LD is apparently increasing and interestingly they are reported more frequently in North America. Data regarding frequency and features of sJIA-LD in Europe are not available. Objectives To evaluate the burden of sJIA-LD in Europe. Methods Patients with diagnosis of sJIA with LD, including pulmonary alveolar proteinosis (PAP), interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH), followed in European paediatric rheumatology centres were identified through a survey sent to the members of the MAS/SJIA Working Party. Results Data from 34 sJIA-LD patients, diagnosed in 15 European paediatric rheumatology centres between 2007 and 2022, were collected. 33 patients were Caucasian and 1 was African-American; 21 were female. The median age at sJIA onset was 6 years and LD occurred after a median time of 2 years. 19 patients had a chronic persistent sJIA course, 14 had a polycyclic course and only 1 patient had a monocyclic course; 29 (85%) had active sJIA at time of LD diagnosis. During the disease course, 28 (82%) patients developed MAS, 12 (35%) of whom had MAS at sJIA onset and 19 (56%) had full-blown MAS at time of LD diagnosis; 23 (68%) patients had >1 MAS episode. 28 (82 %) patients were treated with at least one IL-1 or IL-6 inhibitor before LD diagnosis: 15 with canakinumab, 24 with anakinra and 13 with tocilizumab; 13 (38%) patients experienced drug adverse reaction to a cytokine inhibitor: 9 to tocilizumab and 4 to anakinra. 24 (70%) patients developed ILD, 6 (18%) PAP and 4 (12%) PAH. 15 (44%) patients presented acute digital clubbing; 16 (47%) patients developed hypoxia and 9 (26%) developed pulmonary hypertension. A chest CT scan was performed in all patients with evidence of septal thickening, peri-bronchovascular thickening and ground glass opacities in the majority of patients (26, 18 and 18 respectively). In 17 patients a bronchoalveolar lavage was performed and 12 underwent a lung biopsy. The histopathological pattern was alveolar proteinosis in 5 patients, endogenous lipoid pneumonia in 3, vasculitis in 1 and fibrosis in 1. Half of the patients (17) required ICU admission and 6 (18%) died. All the patients were treated with glucocorticoids (GCs) at time of diagnosis, and 26 received IL-1 or IL-6 inhibitor after the diagnosis (13 canakinumab, 20 anakinra, 14 tocilizumab). Conclusion Lung involvement is an emerging life-threatening complication of sJIA and patients are also diagnosed in Europe. Prompt recognition is crucial and new therapeutic strategies are needed to reduce the risk and improve the outcome of this complication. References [1]Saper VE et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019 Dec;78(12):1722-1731. [2]Schulert GS et al. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors. Arthritis Rheumatol. 2019 Nov;71(11):1943-1954. Acknowledgements MAS/sJIA working party of Pediatric Rheumatology European Society. Disclosure of Interests Claudia Bracaglia Speakers bureau: SOBI, Novartis, Consultant of: SOBI, Francesca Minoia Consultant of: SOBI, christoph kessel Speakers bureau: SOBI, Consultant of: Novartis, Grant/research support from: Novartis, Sebastian Vastert: None declared, Manuela Pardeo Consultant of: SOBI, Alessia Arduini: None declared, Özge Basaran: None declared, Nural Kiper: None declared, Mikhail Kostik: None declared, Mia Glerup: None declared, Sarka Fingerhutova: None declared, Roberta Caorsi Consultant of: SOBI, Novartis, AnnaCarin Horne: None declared, Giovanni Filocamo Consultant of: SOBI, Helmut Wittkowski: None declared, Marija Jelusic: None declared, Jordi Anton Speakers bureau: SOBI, Novimmune, Novartis, GSK, Pfizer., Consultant of: SOBI, Novimmune, Novartis, Pfizer, GSK, Grant/research support from: SOBI, Novimmune, Novartis, Abbvie, Pfizer, GSK, Roche, Amgen, Lilly, BMS, Sanofi, Samira Khaldi-Plassart: None declared, alexandre belot Consultant of: SOBI, Novartis, Roche, Pfizer., Gerd Horneff Speakers bureau: Abbvie, Chugai, Lilly, Sanofi, Novartis, Pfizer, Grant/research support from: MSD, Novartis, Roche, Seraina Palmer Sarott: None declared, Elvira Cannizzaro: None declared, Pavla Doležalová: None declared, Angelo Ravelli: None declared, Seza Ozen Speakers bureau: SOBI, Novartis, Consultant of: SOBI, Novartis, Fabrizio De Benedetti Consultant of: Abbvie, SOBI, Novimmune, Novartis, Roche, Pfizer." @default.
• W4379522772 created "2023-06-07" @default.
• W4379522772 creator A5001567119 @default.
• W4379522772 creator A5008056597 @default.
• W4379522772 creator A5019966799 @default.
• W4379522772 creator A5020507966 @default.
• W4379522772 creator A5022336463 @default.
• W4379522772 creator A5025765870 @default.
• W4379522772 creator A5029874460 @default.
• W4379522772 creator A5030673836 @default.
• W4379522772 creator A5036785123 @default.
• W4379522772 creator A5037623865 @default.
• W4379522772 creator A5038410998 @default.
• W4379522772 creator A5043853010 @default.
• W4379522772 creator A5053719643 @default.
• W4379522772 creator A5055904789 @default.
• W4379522772 creator A5058198905 @default.
• W4379522772 creator A5059134648 @default.
• W4379522772 creator A5059794005 @default.
• W4379522772 creator A5061338585 @default.
• W4379522772 creator A5063047001 @default.
• W4379522772 creator A5074405532 @default.
• W4379522772 creator A5075263570 @default.
• W4379522772 creator A5076916358 @default.
• W4379522772 creator A5079636331 @default.
• W4379522772 creator A5080682222 @default.
• W4379522772 creator A5087156358 @default.
• W4379522772 creator A5091508123 @default.
• W4379522772 date "2023-05-30" @default.
• W4379522772 modified "2023-10-01" @default.
• W4379522772 title "POS0277 SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS ASSOCIATED LUNG DISEASE IN EUROPE" @default.
• W4379522772 doi "https://doi.org/10.1136/annrheumdis-2023-eular.2242" @default.
• W4379522772 hasPublicationYear "2023" @default.
• W4379522772 type Work @default.
• W4379522772 citedByCount "0" @default.
• W4379522772 crossrefType "journal-article" @default.
• W4379522772 hasAuthorship W4379522772A5001567119 @default.
• W4379522772 hasAuthorship W4379522772A5008056597 @default.
• W4379522772 hasAuthorship W4379522772A5019966799 @default.
• W4379522772 hasAuthorship W4379522772A5020507966 @default.
• W4379522772 hasAuthorship W4379522772A5022336463 @default.
• W4379522772 hasAuthorship W4379522772A5025765870 @default.
• W4379522772 hasAuthorship W4379522772A5029874460 @default.
• W4379522772 hasAuthorship W4379522772A5030673836 @default.
• W4379522772 hasAuthorship W4379522772A5036785123 @default.
• W4379522772 hasAuthorship W4379522772A5037623865 @default.
• W4379522772 hasAuthorship W4379522772A5038410998 @default.
• W4379522772 hasAuthorship W4379522772A5043853010 @default.
• W4379522772 hasAuthorship W4379522772A5053719643 @default.
• W4379522772 hasAuthorship W4379522772A5055904789 @default.
• W4379522772 hasAuthorship W4379522772A5058198905 @default.
• W4379522772 hasAuthorship W4379522772A5059134648 @default.
• W4379522772 hasAuthorship W4379522772A5059794005 @default.
• W4379522772 hasAuthorship W4379522772A5061338585 @default.
• W4379522772 hasAuthorship W4379522772A5063047001 @default.
• W4379522772 hasAuthorship W4379522772A5074405532 @default.
• W4379522772 hasAuthorship W4379522772A5075263570 @default.
• W4379522772 hasAuthorship W4379522772A5076916358 @default.
• W4379522772 hasAuthorship W4379522772A5079636331 @default.
• W4379522772 hasAuthorship W4379522772A5080682222 @default.
• W4379522772 hasAuthorship W4379522772A5087156358 @default.
• W4379522772 hasAuthorship W4379522772A5091508123 @default.
• W4379522772 hasBestOaLocation W43795227721 @default.
• W4379522772 hasConcept C126322002 @default.
• W4379522772 hasConcept C187212893 @default.
• W4379522772 hasConcept C198451711 @default.
• W4379522772 hasConcept C2777077863 @default.
• W4379522772 hasConcept C2777178219 @default.
• W4379522772 hasConcept C2777543607 @default.
• W4379522772 hasConcept C2777714996 @default.
• W4379522772 hasConcept C2779134260 @default.
• W4379522772 hasConcept C2779613421 @default.
• W4379522772 hasConcept C2779725882 @default.
• W4379522772 hasConcept C2781228260 @default.
• W4379522772 hasConcept C2909065710 @default.
• W4379522772 hasConcept C2910723750 @default.
• W4379522772 hasConcept C71924100 @default.
• W4379522772 hasConceptScore W4379522772C126322002 @default.
• W4379522772 hasConceptScore W4379522772C187212893 @default.
• W4379522772 hasConceptScore W4379522772C198451711 @default.
• W4379522772 hasConceptScore W4379522772C2777077863 @default.
• W4379522772 hasConceptScore W4379522772C2777178219 @default.
• W4379522772 hasConceptScore W4379522772C2777543607 @default.
• W4379522772 hasConceptScore W4379522772C2777714996 @default.
• W4379522772 hasConceptScore W4379522772C2779134260 @default.
• W4379522772 hasConceptScore W4379522772C2779613421 @default.
• W4379522772 hasConceptScore W4379522772C2779725882 @default.
• W4379522772 hasConceptScore W4379522772C2781228260 @default.
• W4379522772 hasConceptScore W4379522772C2909065710 @default.
• W4379522772 hasConceptScore W4379522772C2910723750 @default.
• W4379522772 hasConceptScore W4379522772C71924100 @default.
• W4379522772 hasIssue "Suppl 1" @default.
• W4379522772 hasLocation W43795227721 @default.
• W4379522772 hasOpenAccess W4379522772 @default.
• W4379522772 hasPrimaryLocation W43795227721 @default.
• W4379522772 hasRelatedWork W1980561047 @default.
• W4379522772 hasRelatedWork W2043790076 @default.
• W4379522772 hasRelatedWork W2066059652 @default.

• next